How close is continuous glucose monitoring to practical preventive medicine?

Can CGM catch problems before standard tests do?

Yes, and in some cases it can spot trouble months or years earlier. In a study of 105 relatives of people with type 1 diabetes, CGM identified individuals who were likely to progress to full-blown disease even when their standard oral glucose tolerance test was still normal [2]. The key warning signs were simple: spending 5% or more of time with glucose above 140 mg/dL, or 5% above 160 mg/dL, each strongly predicted faster progression to stage 3 type 1 diabetes [2]. This matters because it means CGM can flag high-risk people who would otherwise be told everything is fine.

For people without any diabetes diagnosis, CGM can reveal hidden metabolic differences. An analysis of 8,025 non-diabetic adults found that three simple measures—average glucose, how much it varies, and how often it stays high—explained over 80% of the differences between individuals' glucose regulation [5]. These patterns were independently linked to early signs of artery thickening and fatty liver disease, meaning CGM can detect pre-disease states that fasting glucose or HbA1c miss entirely [5].

Does seeing your glucose in real time actually change behavior?

The evidence says yes, and the effect can be substantial. In a randomized trial of 48 adults at risk for heart disease, those who used CGM alongside standard lifestyle advice improved their healthy behaviors significantly more than the control group [9]. Even more striking, when 27 people with prediabetes wore a CGM for just 10 days as part of a diabetes prevention program, 89% completed the session and rated it highly acceptable—and the real-time feedback helped them connect specific foods and activities to glucose spikes [7]. This suggests CGM works as a kind of 'personalized mirror' that makes abstract health advice concrete.

The behavioral effect scales up in larger populations too. A meta-analysis of 15 randomized controlled trials covering 2,461 patients found that CGM use led to a 0.17% drop in HbA1c and an extra 70.74 minutes per day spent in the healthy glucose range [1]. In children starting insulin pump therapy, every extra 100 hours of CGM use per month was linked to a 0.39% lower HbA1c—a meaningful improvement [4]. The common thread is that CGM turns vague guidance into immediate, personal feedback, which drives real changes in what people eat and how active they are.

What are the current limits and risks?

CGM is not a magic bullet, and the evidence shows clear gaps. For preterm infants at risk of dangerous blood sugar swings, a Cochrane review of 4 trials (300 infants) found the data too weak to recommend CGM—the effect on mortality was uncertain, and no studies reported on long-term brain development [3]. This is a reminder that CGM's value depends heavily on the population and the condition.

Even in well-studied areas like diabetes, real-world barriers remain. A large systematic review identified three persistent problems: measurement accuracy can drift in daily life, many users stop wearing the device after a few months (user fatigue), and there is no standard way to connect CGM data to electronic health records [1]. For people on dialysis, a pilot study of 18 patients showed that CGM-guided treatment adjustments improved glucose stability, but the sample was tiny and the effect needs confirmation [6]. And while machine learning can predict glucose levels 60 minutes ahead with 98% clinical safety [8], these predictions have not yet been proven to prevent real-world emergencies in large trials.

About These Sources

This answer is built on 9 peer-reviewed studies — published from 2021 to 2026, 4 from 2024 or later, 3 in Q1 journals, collectively cited 139 times — selected as the most relevant from 10 studies that passed quality screening, drawn from 69 papers retrieved from a database of over 500 million.

Sources used in this answer

Related research questions